Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL‐6/JAK inhibition: A pediatric case series
- 24 July 2021
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (10) , e29261
Abstract
TAFRO (thrombocytopenia, anasarca, fever/elevated C‐reactive protein, reticulin myelofibrosis, renal dysfunction, and organomegaly) clinical subtype of idiopathic multicentric Castleman disease (iMCD‐TAFRO) is a rare lymphoproliferative disease characterized by systemic inflammation. First‐line treatment for iMCD‐TAFRO includes steroids and interleukin (IL)‐6 blockade. Many patients have refractory disease, which is associated with significant morbidity and mortality, and treatment remains challenging. We present two pediatric cases of iMCD‐TAFRO. One patient responded to IL‐6 blockade; the other was refractory to siltuximab and chemotherapy, ultimately responding to JAK inhibition with ruxolitinib. This is the first reported pediatric case of refractory iMCD‐TAFRO responding to JAK inhibition.Keywords
This publication has 14 references indexed in Scilit:
- Increased mTOR activation in idiopathic multicentric Castleman diseaseBlood, 2020
- Overview of Castleman diseaseBlood, 2020
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman diseaseJournal of Clinical Investigation, 2019
- Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two‐site retrospective cohort studyPediatric Blood & Cancer, 2019
- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood, 2017
- Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 versionInternational Journal of Hematology, 2016
- Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman diseaseAmerican Journal of Hematology, 2015
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2014
- The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s diseaseBMC Pediatrics, 2014
- Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012)Journal of Clinical and Experimental Hematopathology, 2013